Litman Gregory Wealth Management LLC Invests $1.21 Million in Zoetis Inc. $ZTS

Key Points

• Litman Gregory Wealth Management LLC invested $1.21 million in Zoetis Inc. by acquiring 7,762 shares during the second quarter.
• Other institutional investors, such as Nuveen LLC and Mackenzie Financial Corp, have significantly increased their stakes in Zoetis, highlighting a trend of growing institutional interest in the company.
• Zoetis has posted strong financial performance, reporting earnings per share (EPS) of $1.76 and revenue of $2.46 billion, surpassing analysts' expectations for both metrics.

Litman Gregory Wealth Management LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 7,762 shares of the company's stock, valued at approximately $1,210,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nuveen LLC bought a new stake in shares of Zoetis in the first quarter worth $616,375,000. Mackenzie Financial Corp lifted its holdings in Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after acquiring an additional 1,782,110 shares during the period. Sarasin & Partners LLP purchased a new position in Zoetis in the first quarter worth about $255,842,000. Polen Capital Management LLC grew its stake in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Finally, Amundi increased its position in shares of Zoetis by 30.8% during the 1st quarter. Amundi now owns 3,595,628 shares of the company's stock valued at $575,691,000 after purchasing an additional 846,909 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Weiss Ratings reissued a "hold (c-)" rating on shares of Zoetis in a report on Saturday, September 27th. Argus reiterated a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $146.45 on Monday. The company has a market capitalization of $64.91 billion, a P/E ratio of 25.21, a P/E/G ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55. The firm's 50 day simple moving average is $149.79 and its two-hundred day simple moving average is $155.02. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.